Erlocip 150mg Tablets, Medicine Type : Oncology Product

Product Overview

Erlocip 150 mg contains Erlotinib, a targeted anti-cancer therapy belonging to the tyrosine kinase inhibitor (TKI) group. It blocks the activity of the epidermal growth factor receptor (EGFR) in cancer cells, slowing their growth and spread.

Indications (Uses)

• Non-Small Cell Lung Cancer (NSCLC), especially advanced or metastatic stages with EGFR mutation
• Pancreatic cancer, in combination with gemcitabine

Dosage & Administration

• Recommended dose: 150 mg once daily, strictly as prescribed by an oncologist
• Should be taken on an empty stomach (1 hour before or 2 hours after meals)
• Dosage and duration depend on patient condition; self-medication should be avoided

Key Benefits

• Targeted therapy for cancers associated with EGFR mutations
• Oral formulation for convenient administration
• Widely used in oncology treatment worldwide

Side Effects

• Common side effects: rash, diarrhea, nausea, appetite loss, fatigue, cough
• Seek urgent medical attention if experiencing severe diarrhea, breathing difficulty, or vision changes

Storage & Handling

• Store below 25°C in a cool, dry place
• Protect from direct sunlight and moisture
• Keep out of reach of children

Safety Information

• Not recommended during pregnancy or breastfeeding
• Avoid smoking, as it reduces drug effectiveness
• Inform the doctor of all concurrent medications before starting therapy
• Regular monitoring of liver function and other tests is required

Certifications

• WHO-GMP Certified
• ISO 9001:2015
• Export Quality Standards

Disclaimer

Erlocip 150 mg is a prescription-only medicine and must be used strictly under the supervision of a qualified healthcare professional. Information provided here is for listing and reference purposes only and should not replace medical advice.